Page last updated: 2024-10-21
n-methyl-3,4-methylenedioxyamphetamine and Social Anxiety Disorder
n-methyl-3,4-methylenedioxyamphetamine has been researched along with Social Anxiety Disorder in 1 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "We discuss how processes of change may extend beyond the MDMA dosing sessions themselves." | 2.82 | Potential processes of change in MDMA-Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships. ( Kati Lear, M; Luoma, JB; Pilecki, B; Shahar, B; Wagner, A, 2022) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Luoma, JB | 1 |
| Shahar, B | 1 |
| Kati Lear, M | 1 |
| Pilecki, B | 1 |
| Wagner, A | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI): A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder[NCT05138068] | Phase 2 | 90 participants (Actual) | Interventional | 2022-04-13 | Active, not recruiting |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
1 review available for n-methyl-3,4-methylenedioxyamphetamine and Social Anxiety Disorder